Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Dysmenorrhea, Menstrual Pain, Endometriosis, Uterine Fibroid
Interventions: Sildenafil citrate vaginal suppository; Drug
Lead sponsor: Kevin Hellman; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Vaginal Personal Care
Interventions: VH-01 vaginal suppository tablet, Placebo vaginal suppository tablet; Other
Lead sponsor: Seed Health; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Bacterial Vaginosis
Interventions: NuvaRing; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
Interventions: Votiva RF; Device
Lead sponsor: Walden, Jennifer L., M.D.,P.L.L.C.; Individual
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • Austin, Texas

Conditions: Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8
Interventions: Discussion, Informational Intervention, Media Intervention, Questionnaire Administration, Telephone-Based Intervention; Procedure · Other · Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Vaginal Atrophy
Interventions: Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%); Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Cleveland, Ohio • Norfolk, Virginia

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: online platform WEBCORE; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohns Disease, Fistula, Rectovaginal Fistula, Complex Perianal Fistula, Complex Cryptoglandular Fistula
Interventions: Not listed
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 9 more

Conditions: Recurrent Bacterial Vaginosis
Interventions: Metronidazole (male partner), Placeob (male partner); Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 50 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pell City, Alabama

Conditions: Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions: Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography; Procedure · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions: Pixel CO2 Laser System; Procedure
Lead sponsor: Alma Lasers Inc.; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions: Point-of-care STI tests, Standard of care STI testing; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: Female only
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Myofacial Pain, Pelvic Pain, Myofascial Pelvic Pain, Chronic Pelvic Pain
Interventions: Near Infrared Imaging; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Carcinoma, Cancer Survivor, Cervical Carcinoma, Dyspareunia, Vaginal Dryness
Interventions: Laser Therapy, Questionnaire Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pelvic Pain, Levator Ani Syndrome, Spastic Pelvic Floor Syndrome, Chronic Pelvic Pain Syndrome, Myalgia of Pelvic Floor
Interventions: SoLá therapy, Pelvic floor physical therapy; Device · Other
Lead sponsor: Orlando VA Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions: Vaginal estradiol tablets, Vaginal moisturizer; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Uterine Atony, Postpartum Hemorrhage
Interventions: Oxytocin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Female only
Enrollment: 1,798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bacterial Vaginosis
Interventions: Metronidazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 26 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Sacral Colpopexy, Pelvic Organ Prolapse
Interventions: Not listed
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Anxiety Disorder, Cervical Cancer, Endometrial Cancer, Female Reproductive Cancer, Gestational Trophoblastic Tumor, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Sexual Dysfunction, Uterine Sarcoma, Vaginal Cancer, Vulvar Cancer
Interventions: informational intervention, counseling intervention, questionnaire administration; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: Tenofovir 1% vaginal gel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Recurrent Urinary Tract Infection
Interventions: Periurethral application of estradiol cream, Intravaginal application of estradiol cream; Drug
Lead sponsor: Stephanie Wang Zuo; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Cranberry Township, Pennsylvania • Erie, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Prolapse
Interventions: anterior vaginal repair (colporrhaphy), abdominal paravaginal defect repair; Procedure
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Microscopic Hematuria
Interventions: Premarin vaginal estrogen cream, Placebo vaginal cream; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Vaginal Sildenafil for Primary Dysmenorrhea

Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study

Topical DHEA Against Vaginal Atrophy

Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

A Study of Surgical Interventions in Fistulizing Conditions

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

Improving Maternal and Child Health Through Point-of-care STI Testing

Measuring Pelvic Floor Muscle Fitness Before and After Treatment

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

Photobiomodulation for Myofascial Pelvic Pain

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

Male Sexual Experience and Its Impact on Quality of Life Before and After Their Sexual Partners Undergo Polypropylene Mesh Augmented Pelvic Floor Reconstruction

Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer

Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery

Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections

Surgical Study Comparing 2 Procedures for the Treatment of a Dropped Bladder

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)